Related Experiment Videos
Sera from patients with malignant mesothelioma can contain autoantibodies
C Robinson1, B W Robinson, R A Lake
1University Department of Medicine, Queen Elizabeth II Medical Centre, Perth, Western Australia, Australia.
Abstract:
Malignant mesothelioma (MM) is resistant to all conventional forms of therapy though there is considerable evidence from clinical trials and animal models of the disease that an immune response can be elicited to the tumour. In order to define those target antigens expressed by MM cells which might provide a focus for an effective immune response we tested patients' sera for the presence of MM autoantibodies by Western blot analysis. Eight of 29 (28%) patients with MM had serum antibodies of the IgG class in high titre and each antiserum recognised different protein antigens. In those individuals where sequential samples were available, the antibody titre increased with the progression of the disease though the number of target antigens remained constant. Sera from the eight patients were studied further: six of the antigen complexes were expressed at least partially in the nucleus; two showed some specificity for the tumour in that they discriminated antigens that were highly expressed in all human MM cell lines, but were not expressed in a human SV40 transformed mesothelial line; four of the antisera recognised a homologue in mouse tissue and each of these had a different pattern of expression. Collectively, these antisera define a subset of nuclear autoantigens that are over-expressed in dividing cells.
Insights
Researchers identified specific autoantibodies in patients with malignant mesothelioma (MM). These antibodies target nuclear autoantigens over-expressed in dividing cells, offering potential for novel immunotherapies against this resistant cancer.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Malignant mesothelioma (MM) exhibits resistance to conventional therapies.
- Evidence suggests that an immune response can be elicited against MM tumors.
- Identifying target antigens is crucial for developing effective immunotherapies.
Purpose of the Study:
- To identify target antigens expressed by MM cells for potential immune response focus.
- To investigate the presence and characteristics of MM-specific autoantibodies in patient sera.
Main Methods:
- Western blot analysis was used to detect MM autoantibodies in patient sera.
- Patient sera were tested for IgG class antibodies against MM cell antigens.
- Characterization of recognized antigens included subcellular localization and expression specificity.
Main Results:
- 28% of MM patients (8/29) had high-titer IgG autoantibodies.
- Each antiserum recognized distinct protein antigens.
- Antibody titers correlated with disease progression.
- Six identified antigen complexes were nuclear; two showed tumor specificity.
- Four antisera recognized mouse tissue homologues with varied expression patterns.
- These antisera collectively define nuclear autoantigens over-expressed in dividing cells.
Conclusions:
- Autoantibodies targeting specific nuclear autoantigens are present in a subset of MM patients.
- These autoantigens are over-expressed in dividing cells, suggesting potential as therapeutic targets.
- Further research into these autoantigens may lead to novel immunotherapeutic strategies for MM.